

1 Evaluation of ComBat harmonization for reducing across- 2 tracer biases in regional amyloid PET analyses

3 Author information

4 Braden Yang¹ (0000-0002-2558-4132), Tom Earnest¹ (0000-0001-8671-8424), Sayantan
5 Kumar¹ (0000-0001-7213-0734), Deydeep Kothapalli¹, Tammie Benzinger¹ (0000-0002-8114-
6 0552), Brian Gordon¹ (0000-0003-2109-2955), Aristeidis Sotiras^{1,2} (0000-0003-0795-8820)

7 ¹ Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis,
8 MO, USA 63110

9 ² Institute for Informatics, Data Science and Biostatistics, Washington University School of Medicine in St.
10 Louis, St. Louis, MO, USA 63110

11 Please address all correspondence to: Braden Yang (b.y.yang@wustl.edu), Aristeidis Sotiras
12 (aristeidis.sotiras@wustl.edu)

13 Abstract

14 Background

15 Differences in amyloid positron emission tomography (PET) radiotracer pharmacokinetics and
16 binding properties lead to discrepancies in amyloid- β uptake estimates. Harmonization of tracer-
17 specific biases is crucial for optimal performance of downstream tasks. Here, we investigated the
18 efficacy of ComBat, a data-driven harmonization model, for reducing tracer-specific biases in
19 regional amyloid PET measurements from [¹⁸F]-florbetapir (FBP) and [¹¹C]-Pittsburgh Compound-
20 B (PiB).

21 **Methods**

22 One-hundred-thirteen head-to-head FBP-PiB scan pairs, scanned from the same subject within
23 ninety days, were selected from the Open Access Series of Imaging Studies 3 (OASIS-3) dataset.
24 The Centiloid scale, ComBat with no covariates, ComBat with biological covariates, and GAM-
25 ComBat with biological covariates were used to harmonize both global and regional amyloid
26 standardized uptake value ratios (SUVR). Intraclass correlation coefficient (ICC) and mean
27 standardized absolute error (MsAE) were computed to measure the absolute agreement between
28 tracers. Additionally, longitudinal amyloid SUVRs from an anti-amyloid drug trial were simulated
29 using linear mixed effects modeling. Differences in rates-of-change between simulated treatment
30 and placebo groups were tested, and change in statistical power/Type-I error after harmonization
31 was quantified.

32 **Results**

33 In the head-to-head tracer comparison, the best ICC and MsAE were achieved after harmonizing
34 with ComBat with no covariates for the global summary SUVR. ComBat with no covariates also
35 performed the best in harmonizing regional SUVRs. In the clinical trial simulation, harmonization
36 with both Centiloid and ComBat increased statistical power of detecting true rate-of-change
37 differences between groups and decreased false discovery rate in the absence of a treatment
38 effect. The greatest benefit of harmonization was observed when groups exhibited differing FBP-
39 to-PiB proportions.

40 **Conclusions**

41 ComBat outperformed the Centiloid scale in harmonizing both global and regional amyloid
42 estimates. Additionally, ComBat improved the detection of rate-of-change differences between
43 clinical trial groups. Our findings suggest that ComBat is a viable alternative to Centiloid for
44 harmonizing regional amyloid PET analyses.

45 **Keywords**

46 Positron emission tomography, amyloid- β , harmonization, Centiloid, ComBat

47 **Background**

48 Positron emission tomography (PET) is widely used in clinical and research settings for measuring
49 and monitoring amyloid- β deposition *in vivo* in the brain for patients who are at risk of developing
50 or who already present with Alzheimer's disease (AD). In clinical trials for anti-amyloid drugs, PET
51 is an important tool for screening appropriate candidates who have undergone significant
52 amyloidosis in the brain [1]. Moreover, PET has also been used for monitoring the progression of
53 global amyloid burden longitudinally within these trials, which along with measures of cognitive
54 function serves as a crucial secondary endpoint [2,3]. In research settings, PET is able to resolve
55 the spatial distribution of amyloid within specific regions of the brain, enabling the design of
56 multivariable statistical analyses and predictive models of AD using voxel-wise [4,5] or region-of-
57 interest (ROI) based [6–8] PET biomarkers as multidimensional features.

58 Several PET radiotracers for imaging brain amyloid pathology have been developed. The first
59 amyloid PET tracer developed for human imaging studies was [^{11}C]-Pittsburg compound B (PiB)
60 [9], but due to its short half-life requires an on-site cyclotron to produce. Consequently, PiB is not
61 accessible by many sites and not appropriate for use in clinical trials. Alternatively, amyloid
62 measurements obtained from ^{18}F -based tracers such as [^{18}F]-florbetapir (FBP) [10–12], [^{18}F]-
63 florbetaben [13] and [^{18}F]-flutemetamol [14,15] have been shown to correlate well with PiB.
64 Coupled with a much longer half-life than PiB, these tracers are a much more suitable option for
65 clinical trials due to their accessibility and ability to be distributed off-site.

66 Nonetheless, previous studies that performed a head-to-head comparison of amyloid PET tracers
67 have demonstrated significant disparities in dynamic range and non-specific binding properties

68 between tracers [10,13,16]. Subsequently, this makes it difficult to compare quantitative amyloid
69 measurements between images acquired using different tracers. This may also negatively impact
70 the performance of downstream tasks such as detecting significant treatment effects in anti-
71 amyloid drug trials [17].

72 To address this, Klunk *et al.* introduced the Centiloid scale [18], which linearly transforms the
73 dynamic range of a global estimate of amyloid burden to a common scale and converts it to
74 Centiloid (CL) units. This involves calibrating the scale to a preselected cohort of amyloid-negative
75 healthy controls and amyloid-positive typical AD patients, where the average global burden of the
76 two groups are set to 0 CL and 100 CL, respectively. However, the calibration process requires
77 at least two PET scans from the same subject within a short time period in order to calibrate
78 conversion equations. Additionally, a single equation is usually derived to operate on the global
79 amyloid estimate, but this cannot address local disparities in amyloid PET signal between tracers.
80 Other methods for tracer harmonization that are based on data-driven and/or machine learning
81 techniques such as principal component analysis [19], non-negative matrix factorization [20], and
82 deep learning [21,22] have been proposed, but like Centiloid they focus on the global amyloid
83 burden.

84 Alternatively, ComBat [23] is a data-driven harmonization model which has been widely applied
85 in magnetic resonance imaging (MRI) analyses to adjust for differences in scanners and
86 acquisition protocols. It has been used to correct regional volume and cortical thickness
87 measurements from MRI [24–27], and has more recently been applied to [¹⁸F]-
88 fluorodeoxyglucose-PET [28] and amyloid PET [29] biomarkers. Much of the current literature on
89 applying ComBat has focused on reducing scanner-level and institutional-level biases. However,
90 it remains unclear whether ComBat is applicable for mitigating across-tracer variance, specifically
91 in regional amyloid PET measurements.

92 Here, we aimed to evaluate the efficacy of ComBat for harmonizing standardized uptake value
93 ratios (SUVR) from amyloid PET across two tracers - PiB and FBP. Specifically, we addressed
94 two primary inquiries. Firstly, we investigated whether ComBat harmonization may increase the
95 agreement between regional SUVRs obtained from the two tracers. This was accomplished
96 through a head-to-head comparison of PiB and FBP. We selected a set of PiB-FBP scan pairs
97 acquired from the same subject in a short time period and compared measures of the absolute
98 agreement between regional SUVRs before and after ComBat harmonization. Secondly, we
99 explored the utility of ComBat harmonization in the context of clinical tasks. This was examined
100 by simulating a multi-tracer anti-amyloid drug trial where two different amyloid tracers were used
101 to measure brain amyloid deposition, under the assumption that different sites have access to
102 different tracers. We generated longitudinal amyloid PET data of hypothetical treatment and
103 placebo groups with a known underlying treatment effect, and assigned each group a specific
104 proportion of PiB-to-AV45 scans. We then gauged whether ComBat harmonization improves the
105 statistical power of detecting the underlying treatment effect when using two different tracers.

106 **Methods**

107 **Participants and data**

108 Data for this study were acquired from the Open Access Series of Imaging Studies 3 (OASIS-3)
109 dataset [30], which consisted of 1098 total participants and their longitudinal imaging data. Of
110 these, we selected 997 who underwent PiB and/or FBP amyloid PET imaging. All available PET
111 scans, including the initial baseline scan and any follow-up scans, were utilized in this study, for
112 a total of 678 FBP scans and 1157 PiB scans. Additionally, each subject's age at scan, sex and
113 apolipoprotein-ε4 (APOE) allele carriership were extracted. Subjects who were missing any of
114 these variables were excluded from further analyses.

115 **Image acquisition and processing**

116 All amyloid PET imaging from OASIS-3 were acquired at Washington University in St. Louis using
117 one of four Siemens scanner models: Biograph mMR PET/MR 3T, Biograph 40 PET/CT, Biograph
118 128 Vision Edge PET/CT, and ECAT HR+ 962 PET. For PiB PET, participants received a bolus
119 injection of 6-20 mCi of PiB, and a 60-minute dynamic scan was acquired. For FBP PET,
120 participants received a bolus injection of 10 mCi of FBP, and either a 70-minute dynamic scan
121 was acquired, or a 20-minute dynamic scan was acquired at 50-minutes post-injection.
122 Additionally, T1-weighted MRI scans were acquired and utilized for PET processing. All MRI
123 imaging from the OASIS-3 dataset were acquired at Washington University in St. Louis using one
124 of three Siemens scanner models: Vision 1.5T, TIM Trio 3T, and Biograph mMR PET/MR 3T.

125 PET images were processed using the PET Unified Pipeline (<https://github.com/ysu001/PUP>),
126 described in [31]. Briefly, raw PET images were smoothed to 8mm spatial resolution, corrected
127 for inter-frame motion, and coregistered to the T1 MRI scan acquired closest in time using a
128 vector-gradient algorithm. T1 images were segmented and parcellated into cortical and
129 subcortical ROIs using FreeSurfer 5.0 or 5.1 for 1.5T scans or FreeSurfer 5.3 for 3T scans. For
130 each ROI, regional SUVRs were computed from the peak time windows of each tracer (30-to-60
131 minutes post-injection for PiB, 50-to-70 minutes post-injection for FBP). The average of the left
132 and right cerebellar cortex was used as the reference region. Additionally, a summary estimate
133 of global amyloid burden was derived by computing the SUVR of a meta-ROI comprised of lateral
134 and medial orbitofrontal, middle and superior temporal, superior frontal, rostral middle frontal, and
135 precuneus ROIs from both hemispheres. For subsequent analyses, we chose to focus on 68
136 cortical, 16 subcortical regions, and the global summary region. The full list of regions is given in
137 Supplementary Table 1.

138 **Data harmonization**

139 Three harmonization methods were investigated in the current study: Centiloid [18], ComBat
140 [23,27], and GAM-ComBat [26]. These methods are briefly described below.

141 **Centiloid**

142 The Centiloid scale [18] is a method of linearly transforming global amyloid burden estimates from
143 SUVRs to a scale that is standardized across tracers. Centiloid ranges from 0 to 100, with 0
144 corresponding to the average amyloid burden of a group of healthy controls, and 100
145 corresponding to the average amyloid burden of typical AD patients. Note that Centiloids are
146 allowed to fall above 100 CL or below 0 CL.

147 Although Centiloid is calibrated against and primarily used to harmonize the global summary
148 SUVR, it can also be applied to regional or voxel-wise SUVRs [17,18]. To convert regional SUVRs
149 to Centiloid, we utilized the conversion equations that were previously validated for the OASIS-3
150 cohort [10,32]:

$$151 \quad \begin{aligned} CL_{PiB} &= 111.8 SUVR_{PiB} - 119.3 \\ CL_{FBP} &= 163.6 SUVR_{FBP} - 181.0 \end{aligned} \quad (1)$$

152 **ComBat**

153 ComBat is a data-driven method for adjusting data with batch-specific effects [23], where batches
154 refer to any nominal variable(s) which may contribute confounding biases in the target
155 measurement. It utilizes a multivariable linear regression to model measurements in terms of
156 batch-specific shift and scale parameters, as well as other covariates which model variance due
157 to biologically relevant effects. For batch effect i , subject j and feature k , ComBat models the
158 measurement y_{ijk} as:

$$159 \quad y_{ijk} = \alpha_k + X_j \beta_k + \gamma_{ik} + \delta_{ik} \epsilon_{ijk} \quad (2)$$

160 where α_k is the mean measurement across all subjects and all batches, X_j is the vector of
161 biological covariates associated with subject j , and β_k is the vector of coefficients for X_j . The
162 batch-specific shift (additive) and scale (multiplicative) parameters are represented by γ_{ik} and δ_{ik}
163 respectively. These modify the measurement from the group average to account for batch-specific
164 biases. ϵ_{ijk} is the error term, which is assumed to be normally distributed with zero mean and unit
165 variance. γ_{ik} and δ_{ik} are estimated using an empirical Baysean approach, and once estimated,
166 the measurement without batch effects can be recovered by the following:

$$167 \quad y_{ijk}^* = \frac{y_{ijk} - \alpha_k - X\beta_k \gamma_{ik}}{\delta_{ik}} + \alpha_k + X\beta_k \quad (3)$$

168 This adjustment ensures that only variance due to the batch effects is corrected for, while variance
169 due to the covariates is preserved, which is a unique advantage of ComBat over other batch-
170 adjusting techniques. In subsequent experiments, we selected age, sex, and APOE carriership
171 as the covariates of interest to preserve.

172 **GAM-ComBat**

173 A limitation of the ComBat model is that it is only able to model covariates as linearly related to
174 the target variable. To address this, Pomponio *et al.* [26] developed GAM-ComBat, a variant of
175 ComBat which can model continuous covariates non-linearly using generalized additive models
176 (GAM):

$$177 \quad y_{ijk} = f(X_j) + \gamma_{ik} + \delta_{ik}\epsilon_{ijk} \quad (4)$$

178 where f is the GAM. In subsequent experiments, we explored modeling the age covariate non-
179 linearly using GAMs.




Fig. 1 Flowchart of data for the tracer head-to-head comparison (left) and clinical trial simulation (right). Dotted arrows indicate where data was used to train ComBat or linear mixed effects models

180 **Statistical analysis**

181 **Tracer head-to-head comparison**

182 We performed a head-to-head comparison of FBP and PiB measurements and evaluated their
 183 absolute agreement after harmonization. We identified 113 FBP-PiB scan pairs across 99
 184 subjects which were acquired within 90 days. All remaining scans were used to train ComBat
 185 models, which included 565 FBP and 1044 PiB scans.

186 Centiloid and three different configurations of ComBat were applied to the global summary SUVR
 187 and 84 regional SUVRs from the head-to-head dataset to harmonize tracer differences. We tested
 188 ComBat without any covariates, ComBat with age, sex and APOE- ϵ 4 carriership as linear
 189 covariates, and GAM-ComBat with sex and APOE- ϵ 4 carriership as linear covariates and age as
 190 a non-linear covariate.

191 To evaluate the absolute agreement between FBP and PiB measurements, two metrics were
192 computed. Firstly, intraclass correlation coefficient (ICC) using a fixed rater, single measurement
193 model (i.e. ICC3) was estimated. ICC is roughly the ratio of intraclass variance to total variance,
194 and values closer to 1 indicate better agreement between the two tracers. Secondly, we derived
195 a standardized version of the mean absolute error between PiB and FBP measurements, which
196 we termed mean standardized absolute error (MsAE). Standardization was performed to allow for
197 comparisons of absolute errors between Centiloids and SUVRs, which otherwise have different
198 dynamic ranges. To standardize errors, we used the following formulae:

199
$$\Delta_i = \text{abs}(PiB_i - FBP_i) \quad (5)$$

200
$$MsAE = \frac{1}{N} \sum_{i=1}^N \frac{\Delta_i}{\sigma_{\Delta_i}} \quad (6)$$

201 where PiB_i and FBP_i are the measurements made with PiB and FBP from scan pair i , N is the
202 number of scan pairs, and σ_{Δ_i} is the standard deviation of the absolute differences:

203
$$\sigma_{\Delta_i} = \sqrt{\frac{\sum_{i=1}^N (\Delta_i - \bar{\Delta})^2}{N-1}} \quad (7)$$

204 Paired t-tests were performed to test for significant differences in the distributions of ICC and
205 MsAE between unharmonized SUVRs and each of the four harmonization methods. Additionally,
206 we further subdivided each FreeSurfer region into three groups – regions belonging to the global
207 summary meta-ROI, other cortical regions not part of the summary meta-ROI, and subcortical
208 regions. We then performed paired t-tests for each group separately to compare across
209 harmonization methods. In all statistical tests, Bonferroni correction was applied to correct for
210 multiple comparisons.

211 **Clinical trial simulation**

212 We evaluated Centiloid and ComBat in the context of improving detection of treatment effects in
213 an anti-amyloid drug trial setting, with the assumption that multiple amyloid PET tracers were
214 used due to pooling of data from multiple institutions. To accomplish this, we modeled a simulation
215 experiment after those described in Chen *et al.* [17] to generate data of placebo and treatment
216 groups. We varied the proportion of FBP-to-PiB scans of each group, then tested for group
217 differences of amyloid rate-of-change.

218 We selected subjects who presented as PET amyloid-positive at least once during their
219 participation in OASIS-3. To mark scans as amyloid-positive, we used a global summary SUVR
220 threshold of 1.31 for PiB and 1.24 for FBP. These thresholds were previously validated for the
221 OASIS-3 cohort [10]. From these criteria, we identified 363 amyloid-positive subjects, from which
222 258 FBP and 322 PiB scans were selected.

223 For each tracer and for each region-of-interest (including the global summary region), a linear
224 mixed effects (LME) model was fit on the selected scans to predict longitudinal SUVR. Sex, APOE
225 carriership, baseline age, and time-from-baseline were specified as fixed effects. A random
226 intercept grouped by subject was specified as the only random effect. Fitted LME models were
227 then used to generate new longitudinal data of placebo and treatment groups. For the placebo
228 group, the models were applied as is to generate SUVRs that follow the natural longitudinal
229 trajectory among amyloid-positive subjects in OASIS-3. For the treatment group, we added a
230 negative rate-of-change term to the LME equation to mimic a treatment effect. We tested multiple
231 values of the treatment effect from 0 to -0.03 SUVR, varying in increments of -0.01 SUVR. These
232 values were chosen based off of previously reported clinical trial effect sizes [2,17].

233 To simulate a single subject's data, the empirical distributions of number of longitudinal scans,
234 age at baseline scan, and interval between scans among the OASIS-3 amyloid-positive cohort

235 were randomly sampled to generate longitudinal time points. We then randomly assigned each
236 time point a tracer (either PiB or FBP) according to a prespecified tracer mixing proportion. Time
237 points were then fed into the trained LME model to obtain simulated SUVR measurements. For
238 these simulation experiments, we varied the percentage of FBP scans from 0.1 to 0.9 in
239 increments of 0.2 for both clinical trial groups independently. We fixed the number of subjects to
240 50 per group.

241 The simulated data was harmonized using either Centiloid, ComBat with no covariates, or
242 ComBat with age, sex and APOE- ϵ 4 carriership as covariates. ComBat was trained on the same
243 data used to train the generative LME models. Note that we omitted GAM-ComBat from this
244 analysis, since the simulated data was generated using a linear age term in the LME. To test for
245 group differences in the rate-of-change in amyloid SUVR between placebo and treatment groups,
246 we first fitted the same LME described previously, but with two additional terms – clinical trial
247 group and interaction of time-from-baseline with trial group. We then tested for statistical
248 significance of the time-from-baseline and clinical trial group interaction term, which would
249 indicate whether the two groups exhibit different rates-of-change. Likelihood ratio tests were used
250 to compare the fit of the full model with a nested model that excludes this term, and significance
251 was determined using $\alpha = 0.05$. Simulations were repeated 1000 times for each permutation of
252 tracer mixing proportions and treatment effect. Statistical power was computed as the proportion
253 of simulation iterations which resulted in a significant finding. Note that for a treatment effect of
254 zero, i.e. the absence of a ground truth treatment effect, this corresponds to the Type-I error rate.

255 Results

256 Demographics

257 Descriptive statistics of each cohort are listed in Table 1. A two-tailed t-test was used to test for
 258 differences in age at scan, and Fisher's exact test was used to test for differences in sex, APOE-
 259 $\epsilon 4$, and Clinical Dementia Rating (CDR). Significant differences in age were observed between

Table 1 Demographics of each cohort. Note that the reported CDRs are counted by scans, where the closest CDR score in time was assigned to every scan. Statistically significant differences are denoted with asterisks and crosses. Asterisks indicate tracer vs. tracer comparisons within the same cohort, whereas crosses indicate cohort vs. cohort comparisons within the same tracer. The number of symbols indicates the significance level (1 = $p < 0.05$, 2 = $p < 0.01$, 3 = $p < 0.005$, 4 = $p < 1e-4$)

	Tracer head-to-head comparison				Simulation	
	head-to-head		training		FBP	PiB
	FBP	PiB	FBP	PiB		
Number of subjects	99	99	520	671	213	210
Number of scans	113	113	565	1044	258	322
Mean age at scan (\pm sd) ¹	69.1 \pm 8.48	69 \pm 8.48	71.6 \pm 8 ^{††}	68.9 \pm 9.37 ^{*****}	73.5 \pm 7.18	73.1 \pm 7.34
Number of males/females	45/54	45/54	223/297	283/388	77/136	106/104 [*]
APOE noncarriers/carriers ²	67/32	67/32	337/183	441/230	104/109	78/132 [*]
Number of CDR = 0/CDR = 0.5/CDR > 1 ³	108/4/1	108/4/1	480/67/18 [†]	900/118/26 [†]	189/53/16	232/68/22
Number of scans per subject (\pm sd)	1.1 \pm 0.38	1.1 \pm 0.38	1.1 \pm 0.29	1.6 \pm 0.82	1.2 \pm 0.49	1.5 \pm 0.88
Mean years between scans (\pm sd)	1.6 \pm 0.54	1.6 \pm 0.53	3 \pm 0.86	3.8 \pm 2.01	2.1 \pm 1.06	3.3 \pm 1.52

* = significance of tracer vs. tracer comparison (within same cohort)

† = significance of cohort vs. cohort comparison (within same tracer)

¹ sd = standard deviation

² APOE = apolipoprotein- $\epsilon 4$

³ CDR = Clinical Dementia Rating




Fig. 2 Global summary measures computed from PiB and FBP scans in the tracer head-to-head dataset. The red line indicates the best fit line from OLS linear regression, the gray area indicates confidence interval of the slope, and the black line represents the identity line




Fig. 3 Distribution of regional ICC across all ROI, grouped by harmonization method and ROI subgroup. Each point represents a single ROI. Significance levels from paired t-tests with Bonferroni correction are indicated for each pair of harmonization methods (* = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.005$, **** = $p < 1e-4$)

260 FBP and PiB groups within the training set ($p < 1e-4$), and between the training and head-to-head
 261 cohorts in FBP only ($p < 0.01$). CDR status also differed between training and head-to-head
 262 cohorts in both FBP and PiB ($p < 0.05$). In the simulation cohort, sex and APOE- $\epsilon 4$ were different
 263 between FBP and PiB groups ($p < 0.05$).

264 Tracer head-to-head comparison

265 We evaluated the ability of Centiloid and ComBat to improve the absolute agreement between
 266 FBP and PiB using the head-to-head dataset. For the global summary region, absolute
 267 agreement, as measured by ICC, increased after harmonization with either Centiloid ($ICC =$




Fig. 4 Standardized absolute error of the global summary measure from each PiB and FBP scan pair in the tracer head-to-head dataset. Each point represents a single scan pair. Significance levels from paired t-tests with Bonferroni correction are indicated for each pair of harmonization methods (* = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.005$, **** = $p < 1e-4$)




Fig. 5 Distribution of regional MsAE across all ROI, grouped by harmonization method and ROI subgroup. Each point represents a single ROI. Significance levels from paired t-tests with Bonferroni correction are indicated for each pair of harmonization methods (* = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.005$, **** = $p < 1e-4$)

268 0.912) or ComBat with no covariates ($ICC = 0.916$), compared to the unharmonized SUVR ($ICC =$
 269 0.882) (Table 2, Fig. 2). ICC also increased slightly after harmonization with ComBat with
 270 covariates and GAM-ComBat ($ICC = 0.898$), albeit not to the same degree as Centiloid or ComBat
 271 with no covariates. For ROI measurements, all three ComBat harmonization methods led to a
 272 statistically significant increase in average ICC among all ROIs compared to unharmonized SUVR

273 ($p < 1e-4$), with ComBat with no covariates again performing the best ($\overline{ICC} = 0.838$) (Table 2, Fig.
 274 3a). Additionally, ComBat with no covariates performed the best within the summary cortical ROIs
 275 ($\overline{ICC} = 0.899$) and other cortical ROIs ($\overline{ICC} = 0.853$) (Fig. 3b-c). No method was effective at
 276 improving across-tracer agreement for the subcortical ROIs (Fig. 3d). When focusing on each
 277 ROI individually, Centiloid resulted in a decrease in ICC in the bilateral occipital and sensorimotor
 278 regions, and in the left temporal and parietal cortices (Supp. Fig. 1b). In contrast, none of the
 279 ComBat variants led to such decrease in these regions (Supp. Fig. 1c-e).

280 These trends were consistent when assessing the standardized absolute error between FBP and
 281 PiB measurements of the global summary region (Table 2, Fig. 4). ComBat with no covariates
 282 was the only method that reduced the mean error with statistical significance ($MsAE = 1.07$, $p <$
 283 0.05) compared to unharmonized SUVRs ($MsAE = 1.335$). For ROI measurements, all methods
 284 significantly reduced the average MsAE among all ROIs ($p < 0.01$), but ComBat with no covariates
 285 resulted in the greatest reduction ($\overline{MsAE} = 1.12$) (Table 2, Fig. 5a). ComBat with no covariates
 286 also performed the best within the summary cortical ROI ($\overline{MsAE} = 1.048$) and other cortical ROIs

Table 2 Mean \pm standard deviation of ICC and MsAE from the tracer head-to-head comparison. The mean across subjects was computed for the global summary region, whereas the mean across ROIs was computed for the FreeSurfer ROI. Bold values indicate the best performing harmonization method. Asterisks indicate statistical significance of paired t-tests comparing each harmonization method with unharmonized (* = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.005$, **** = $p < 1e-4$). Note that the standard deviation of standardized absolute error (second column) is

always one by design (see Equations $\Delta_i = \text{abs}(PiB_i - FBP_i)$ (5 through $\sigma_{\Delta_i} = \sqrt{\frac{\sum_{i=1}^N (\Delta_i - \bar{\Delta})^2}{N-1}}$)
 (7)

Harmonization method	All ROI		Summary cortical ROI		Other cortical ROI		Subcortical ROI			
	ICC	MsAE	ICC	MsAE	ICC	MsAE	ICC	MsAE		
unharmonized	0.882	1.335 \pm 1	0.819 \pm 0.077	1.369 \pm 0.26	0.866 \pm 0.03	1.308 \pm 0.255	0.838 \pm 0.048	1.403 \pm 0.259	0.701 \pm 0.089	1.299 \pm 0.26
centiloid	0.912	1.181 \pm 1	0.811 \pm 0.098	1.249 \pm 0.196**	0.891 \pm 0.018	1.139 \pm 0.181	0.822 \pm 0.063	1.254 \pm 0.206**	0.686 \pm 0.137	1.341 \pm 0.108
ComBat, no covariates	0.916	1.07 \pm 1*	0.838 \pm 0.083****	1.12 \pm 0.123****	0.899 \pm 0.018**	1.048 \pm 0.11*	0.853 \pm 0.05****	1.115 \pm 0.116****	0.72 \pm 0.111	1.212 \pm 0.112
ComBat + age, sex, APOE	0.898	1.325 \pm 1	0.827 \pm 0.08****	1.229 \pm 0.112**	0.881 \pm 0.024**	1.233 \pm 0.098	0.844 \pm 0.049**	1.223 \pm 0.116**	0.707 \pm 0.099	1.248 \pm 0.115
GAM-ComBat + age, sex, APOE	0.898	1.326 \pm 1	0.827 \pm 0.08****	1.234 \pm 0.113**	0.881 \pm 0.024**	1.241 \pm 0.096	0.844 \pm 0.049****	1.227 \pm 0.117**	0.707 \pm 0.099	1.255 \pm 0.118




Fig. 6 Statistical power of detecting group differences in rate-of-change of the global summary SUVR between treatment and placebo groups, computed as the proportion of significant findings over 1000 iterations. Power is plotted for unharmonized SUVR, while difference in power relative to unharmonized is plotted for all harmonization methods. The true underlying rate-of-change is varied across columns. The proportion of FBP scans in the placebo and treatment groups are varied across the horizontal and vertical axes, respectively. Note that for annualized rate-of-change equal to zero, the proportion of significant findings corresponds to Type-I error rate

287 $(\overline{MsAE} = 1.115)$ (Fig. 5b-c). Again, no method was able to significantly reduce error in the
 288 subcortical regions (Fig. 5d).

289 **Clinical trial simulation**

290 We performed simulations to test for group differences in amyloid rate-of-change between
291 treatment and placebo groups in a hypothetical clinical trial, and evaluated whether harmonization
292 improved the ability of detecting these differences. For the global summary SUVR, both Centiloid
293 and ComBat resulted in overall increases in statistical power after harmonization in the presence
294 of a treatment effect (i.e. for rate-of-change $\in \{-0.01, -0.02, -0.03\}$), primarily when the placebo
295 group had high FBP composition and the treatment group had low FBP composition (Fig. 6). The
296 greatest benefit of harmonization was observed for rate-of-change = -0.02. In the absence of a
297 treatment effect (i.e. rate-of-change = 0), Centiloid and ComBat achieved decreases in Type-I
298 error, primarily when the placebo group had low FBP composition and the treatment group had
299 high FBP composition. Similar patterns of change in power were observed when using ComBat
300 with covariates, albeit to a lesser magnitude. For regional SUVRs, surface plots of the statistical
301 power reveal similar patterns of change in power for most regions (Supp. Fig. 3-4).

302 **Discussion**

303 We demonstrated that ComBat may effectively harmonize amyloid PET measurements across
304 FBP and PiB. Notably, ComBat with no covariates outperformed Centiloid in increasing absolute
305 agreement between tracers in both the global summary and regional measurements, and resulted
306 in a comparable improvement in detecting group differences in the simulated clinical trial. As more
307 studies shift focus from using a global summary metric of amyloid burden to using the spatial
308 distribution of regional amyloid as features [6,7], harmonization techniques like ComBat that can
309 be applied to multiple regions become appealing for pooling PET data across multiple tracers.
310 ComBat poses several methodological advantages over Centiloid. Firstly, whereas calibration of
311 Centiloid requires *a priori* selection of representative individuals from healthy control and typical

312 AD cohorts, training ComBat requires no such step. This *a priori* cohort selection may introduce
313 bias into the calibration process. Especially if the selected sample is small and/or captures only a
314 subset of the overall population (e.g. biased towards a single ethnicity group), Centiloid may not
315 generalize well to heterogeneous or out-of-sample datasets. ComBat circumvents this
316 requirement, which allows it to learn a robust harmonization on a potentially more varied dataset
317 which consists of controls, AD patients and “in-between” subjects. Furthermore, much like
318 Centiloid, a trained ComBat model may then be used to harmonize out-of-sample data. Secondly,
319 Centiloid requires at least two PET scans of different tracers for each subject in the calibration
320 cohort, one of which should be acquired using PiB. In contrast, ComBat can train using just one
321 scan per subject and does not require PiB to be used. Thirdly, a region-specific harmonization is
322 important for addressing sources of tracer bias which variably affect different regions, such as
323 non-specific binding [33]. However, as suggested by Klunk et al. [18], a region-specific Centiloid
324 calibration is not ideal, since it would fix different SUVRs of different regions to the same Centiloid
325 value. In contrast, ComBat independently removes the tracer-specific variance from the target
326 measurements without scaling the dynamic range of each region to fixed points, making it a more
327 suitable technique for regional harmonization.

328 Lastly, ComBat has the advantage of being able to preserve covariate relationships in the target
329 measurement, which may be useful in downstream analyses such as in predictive models which
330 take into account biologically-related variance to make accurate predictions. However, in the
331 context of purely evaluating the absolute agreement between tracers, we observed that including
332 covariates into the ComBat model led to worse ICC and absolute errors. This may be partially
333 due to differences in covariate distributions between the training and head-to-head cohorts, of
334 which age and CDR differed with statistical significance. Although CDR was not explicitly included
335 as a ComBat covariate, it may have indirectly contributed to a biased ComBat model which does
336 not generalize well to testing data with different covariate characteristics.

337 It was noted that no harmonization method investigated in this study performed well for the
338 subcortical regions. Notably, these regions lie close to white matter regions, and thus may be
339 affected by non-specific binding more so than cortical regions. This may contribute to more noise
340 in the subcortical regions, which batch harmonization methods such as ComBat are not able to
341 mitigate. One potential area of investigation is to evaluate whether partial volume correction [33]
342 would have an effect on regional harmonization of PET SUVRs, especially for regions which
343 experience high amounts of signal spill-over from neighboring white matter regions.

344 Our simulation experiments revealed the importance of harmonization in settings where multiple
345 tracers are utilized to track brain amyloid deposition in clinical trial participants. Particularly,
346 harmonization was the most beneficial when trial groups exhibited differing proportions of tracer
347 data. In these cases, tracer biases contributed to a substantial confounding effect across clinical
348 trial groups, resulting in either a reduction of power in detecting the true underlying treatment
349 effect, or an increase in Type-I error in the case when no treatment effect exists. Harmonization
350 effectively served to mitigate these confounding effects due to tracer differences. This was
351 consistent with previous reports that found significant differences in amyloid rates-of-change
352 across different tracers within real clinical trial groups, and that these differences were
353 subsequently removed after harmonization [17]. Little change was observed in power when
354 clinical trial groups exhibited the same proportion of tracer data, likely due to the fact that the
355 same tracer bias would affect both groups equally, which statistically would not influence the
356 detection of group differences.

357 There are several limitations to the current work. Firstly, on the basis of purely increasing tracer
358 agreement, there are no clear recommendations on the choice of including covariates in ComBat.
359 One caveat to using ComBat is that, unless explicitly accounted for in the covariates, it will assume
360 that any biases due to real biological differences between tracer cohorts are batch differences,
361 which are subsequently removed. Therefore, one should carefully examine the composition of the

362 data at hand and consider whether it is necessary to model known biological factors via the
363 covariate terms. Secondly, data from the simulation experiment were generated from models
364 trained on a cohort of amyloid-positive subjects from OASIS-3 instead of data from an actual anti-
365 amyloid drug trial. Although simulations were set up to mimic data that would be collected in a
366 successful trial, it remains to be seen whether our hypotheses would hold on real-world clinical
367 trial data. Finally, ComBat assumes that the target features (after residualizing covariate terms)
368 are distributed normally. However, this is often not the case for amyloid imaging data, where the
369 distribution of amyloid burden across subjects often exhibits a bimodal pattern of low amyloid
370 (amyloid-negative) and high amyloid (amyloid-positive) clusters. Recently developed
371 harmonization techniques such as NoDiM [34] and PEACE [29] explicitly model the target as a
372 multi-modal Gaussian mixture. This allows for the batch-specific shifts and scales to be adjusted
373 independently for each cluster. However, neither study focused specifically on regional
374 harmonization of tracer-specific effects. Adapting a cluster-specific harmonization technique for
375 this task is thus an interesting avenue for future investigation, as this framework may be more
376 suitable for amyloid PET imaging data.

377 **Conclusions**

378 Harmonization of amyloid PET radiotracers is imperative for removing tracer-specific biases in
379 amyloid burden measurements for optimal performance of downstream tasks, such as enhancing
380 statistical power and reducing false discoveries in clinical trials. In the current study, we
381 demonstrated that ComBat is effective for harmonizing both global and regional amyloid
382 measurements in an entirely data-driven way. Our experimental results suggest that ComBat not
383 only increases the absolute agreement of measurements made by different tracers, but also
384 provides a significant benefit to the performance of detecting true treatment effects in anti-amyloid

385 drug trials. ComBat thus presents as a viable technique for harmonizing regional-based analyses
386 of amyloid PET.

387 **List of Abbreviations**

388 PET: positron emission tomography; FBP: [¹⁸F]-florbetapir; PiB: [¹¹C]-Pittsburgh Compound-B;
389 OASIS-3: Open Access Series of Imaging Studies 3; SUVR: standardized uptake value ratio;
390 ICC: intraclass correlation coefficient; MsAE: mean standardized absolute error; AD:
391 Alzheimer's disease; ROI: region-of-interest; CL: Centiloid; MRI: magnetic resonance imaging;
392 APOE: apolipoprotein-ε4; GAM: generalized additive model; LME: linear mixed effects; CDR:
393 Clinical Dementia Rating.

394 **Supplementary Information**

395 **Additional file 1.docx** - Supplementary figures and tables. **Supp. Table 1:** List of FreeSurfer
396 regions-of-interest used in the study, along with their subgroupings. **Supp. Fig. 1:** Regional
397 ICCs plotted on the surface from the tracer head-to-head comparison. **Supp. Fig. 2:** Regional
398 MsAEs plotted on the surface from the tracer head-to-head comparison. **Supp. Fig. 3:** Surface
399 plots of mean statistical power from the simulation experiment. **Supp. Fig. 4:** Subcortical plots
400 of mean statistical power from the simulation experiment. **Supp. Table 2:** Mean statistical power
401 of detecting significant rate-of-change differences between treatment and placebo groups in the
402 simulation experiment for the global summary amyloid estimate. **Supp. Table 3:** Mean statistical
403 power of detecting significant rate-of-change differences between treatment and placebo groups
404 in the simulation experiment for the ROI amyloid measurements.

405 **Declarations**

406 **Ethics approval and consent to participate**

407 Ethics approvals were obtained by the OASIS-3 dataset. All participants were consented into
408 Knight ADRC-related projects in accordance with the Declaration of Helsinki and following
409 procedures approved by the Institutional Review Board of Washington University School of
410 Medicine in St. Louis. For more details, we refer the reader to the OASIS-3 reference.

411 **Consent for publication**

412 Not applicable

413 **Availability of data and materials**

414 Data utilized in this study were obtained from the OASIS-3 open access dataset. Data can be
415 requested at <https://sites.wustl.edu/oasisbrains>.

416 Code for this study will be made publicly available at <https://github.com/sotiraslab>. All statistical
417 analyses and simulation experiments were implemented using R version 4.3.2 and python version
418 3.10.10. The *neuroharmonize* python package (<https://github.com/rpomponio/neuroHarmonize>)
419 was used to train and apply ComBat and GAM-ComBat models.

420 **Competing Interests**

421 AS reported receiving personal fees from BrightFocus for serving as a grant reviewer and stock
422 from TheraPanacea outside the submitted work. All remaining authors have no conflicting
423 interests to report.

424 **Funding**

425 BY was supported by the Imaging Science Pathways NIH T32 EB014855. AS was supported by
426 NIH award R01 AG067103 and BrightFocus Foundation grant ADR A2021042S.

427 Computations were performed using the facilities of the Washington University Research
428 Computing and Informatics Facility, which were partially funded by NIH grants S10OD025200,
429 1S10RR022984-01A1 and 1S10OD018091-01. Additional support is provided by The
430 McDonnell Center for Systems Neuroscience.

431 **Authors' contributions**

432 All authors contributed to the conceptualization and design of the study. BY implemented all
433 data analyses and experiments and wrote the first draft of the manuscript. AS, BG and TB
434 contributed to the interpretation of data. TE, SK and DK provided technical support. All authors
435 were involved with manuscript revision, and all approved of the final draft.

436 **Acknowledgements**

437 Acknowledgement is made to the donors of the ADR A2021042S, a program of the BrightFocus
438 Foundation, for support of this research. Data were provided by OASIS-3: Longitudinal Multimodal
439 Neuroimaging (Principal Investigators: T. Benzinger, D. Marcus, J. Morris). OASIS-3 was
440 supported by the following funding sources: NIH P50 AG00561, P30 NS09857781, P01
441 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were
442 provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.

443 **References**

- 444 1. Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The Role of Amyloid PET in
445 Imaging Neurodegenerative Disorders: A Review. *J Nucl Med.* 2022;63:13S-19S.
- 446 2. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-
447 blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an
448 anti-A β protofibril antibody. *Alz Res Therapy.* 2021;13:80.

- 449 3. Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association
450 of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes:
451 The TRAILBLAZER-ALZ Randomized Clinical Trial. *JAMA Neurology*. 2022;79:1015–24.
- 452 4. Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MS, Beaudry T, et al. Identifying
453 incipient dementia individuals using machine learning and amyloid imaging. *Neurobiology of*
454 *Aging*. 2017;59:80–90.
- 455 5. Choi H, Jin KH. Predicting cognitive decline with deep learning of brain metabolism and
456 amyloid imaging. *Behavioural Brain Research*. 2018;344:103–9.
- 457 6. Pfeil J, Hoenig MC, Doering E, van Eimeren T, Drzezga A, Bischof GN. Unique regional
458 patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer’s
459 disease. *Neurobiology of Aging*. 2021;106:119–29.
- 460 7. Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, et al.
461 Topographical distribution of A β predicts progression to dementia in A β positive mild cognitive
462 impairment. *Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring*.
463 2020;12:e12037.
- 464 8. Ezzati A, Abdulkadir A, Jack CR, Thompson PM, Harvey DJ, Truelove-Hill M, et al. Predictive
465 value of ATN biomarker profiles in estimating disease progression in Alzheimer’s disease
466 dementia. *Alzheimer’s & Dementia*. 2021;17:1855–67.
- 467 9. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid
468 in Alzheimer’s disease with Pittsburgh Compound-B. *Annals of Neurology*. 2004;55:306–19.

- 469 10. Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, et al. Comparison of
470 Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. *Alzheimer's &*
471 *Dementia: Diagnosis, Assessment & Disease Monitoring*. 2019;11:180–90.
- 472 11. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in
473 Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission
474 tomography. *J Neurol Neurosurg Psychiatry*. 2012;83:923–6.
- 475 12. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid- β
476 Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and
477 Quantification Methods. *Journal of Nuclear Medicine*. 2013;54:70–7.
- 478 13. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, et al. Comparison of
479 ^{11}C -PiB and ^{18}F -florbetaben for A β imaging in ageing and Alzheimer's disease. *Eur J Nucl*
480 *Med Mol Imaging*. 2012;39:983–9.
- 481 14. Adamczuk K, Schaefferbeke J, Nelissen N, Neyens V, Vandebulcke M, Goffin K, et al.
482 Amyloid imaging in cognitively normal older adults: comparison between ^{18}F -flutemetamol and
483 ^{11}C -Pittsburgh compound B. *Eur J Nucl Med Mol Imaging*. 2016;43:142–51.
- 484 15. Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, et al. Comparison of
485 qualitative and quantitative imaging characteristics of ^{11}C PiB and ^{18}F flutemetamol in normal
486 control and Alzheimer's subjects. *NeuroImage: Clinical*. 2015;9:592–8.
- 487 16. Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET
488 imaging in Alzheimer's disease: a comparison of three radiotracers. *Eur J Nucl Med Mol*
489 *Imaging*. 2014;41:1398–407.

- 490 17. Chen CD, McCullough A, Gordon B, Joseph-Mathurin N, Flores S, McKay NS, et al.
491 Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3
492 clinical trial of anti-amyloid- β monoclonal antibodies in dominantly inherited Alzheimer's disease.
493 Eur J Nucl Med Mol Imaging. 2023;50:2669–82.
- 494 18. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Sr. MD, Jagust WJ, et al. The
495 Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer's &
496 Dementia. 2015;11:1-15.e4.
- 497 19. Pegueroles J, Montal V, Bejanin A, Vilaplana E, Aranha M, Santos-Santos MA, et al. AMYQ:
498 An index to standardize quantitative amyloid load across PET tracers. Alzheimer's & Dementia.
499 2021;17:1499–508.
- 500 20. Bourgeat P, Doré V, Doecke J, Ames D, Masters CL, Rowe CC, et al. Non-negative matrix
501 factorisation improves Centiloid robustness in longitudinal studies. NeuroImage.
502 2021;226:117593.
- 503 21. Chen K, Ghisays V, Luo J, Chen Y, Lee W, Wu T, et al. Harmonizing florbetapir and PiB
504 PET measurements of cortical A β plaque burden using multiple regions-of-interest and machine
505 learning techniques: An alternative to the Centiloid approach. Alzheimer's & Dementia.
506 2024;20:2165–72.
- 507 22. Liu H, Nai Y-H, Saridin F, Tanaka T, O' Doherty J, Hilal S, et al. Improved amyloid burden
508 quantification with nonspecific estimates using deep learning. Eur J Nucl Med Mol Imaging.
509 2021;48:1842–53.
- 510 23. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using
511 empirical Bayes methods. Biostatistics. 2007;8:118–27.

- 512 24. Richter S, Winzeck S, Correia MM, Kornaropoulos EN, Manktelow A, Outtrim J, et al.
513 Validation of cross-sectional and longitudinal ComBat harmonization methods for magnetic
514 resonance imaging data on a travelling subject cohort. *Neuroimage: Reports*. 2022;2:100136.
- 515 25. Sun D, Rakesh G, Haswell CC, Logue M, Baird CL, O’Leary EN, et al. A comparison of
516 methods to harmonize cortical thickness measurements across scanners and sites.
517 *NeuroImage*. 2022;261:119509.
- 518 26. Pomponio R, Erus G, Habes M, Doshi J, Srinivasan D, Mamourian E, et al. Harmonization
519 of large MRI datasets for the analysis of brain imaging patterns throughout the lifespan.
520 *NeuroImage*. 2020;208:116450.
- 521 27. Fortin J-P, Cullen N, Sheline YI, Taylor WD, Aselcioglu I, Cook PA, et al. Harmonization of
522 cortical thickness measurements across scanners and sites. *NeuroImage*. 2018;167:104–20.
- 523 28. Leithner D, Schöder H, Haug A, Vargas HA, Gibbs P, Häggström I, et al. Impact of ComBat
524 Harmonization on PET Radiomics-Based Tissue Classification: A Dual-Center PET/MRI and
525 PET/CT Study. *Journal of Nuclear Medicine*. 2022;63:1611–6.
- 526 29. Bilgel M. Probabilistic estimation for across-batch compatibility enhancement for amyloid
527 PET. *Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2023;15:e12436.
- 528 30. LaMontagne PJ, Benzinger TLS, Morris JC, Keefe S, Hornbeck R, Xiong C, et al. OASIS-3:
529 Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer
530 Disease. *medRxiv*. 2019;2019.12.13.19014902.
- 531 31. Su Y, D’Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, et al. Quantitative
532 Analysis of PiB-PET with FreeSurfer ROIs. *PLOS ONE*. 2013;8:e73377.

- 533 32. Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, et al. Utilizing the
534 Centiloid scale in cross-sectional and longitudinal PiB PET studies. *NeuroImage: Clinical*.
535 2018;19:406–16.
- 536 33. Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, et al. Partial volume
537 correction in quantitative amyloid imaging. *NeuroImage*. 2015;107:55–64.
- 538 34. Properzi MJ, Buckley RF, Chhatwal JP, Donohue MC, Lois C, Mormino EC, et al. Nonlinear
539 Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers.
540 *NeuroImage*. 2019;186:446–54.